Modification of the disease process in MCI by high-dose B vitamins (VITACOG trial)

Date & time

10.30am 14 August 2014


Bob Douglas Lecture Theatre, building 62A, Eggleston Road, ANU


Professor David A Smith


 Trina Merrell

The importance of subgroups: Elevated levels of plasma total homocysteine are an established risk factor for Alzheimer’s disease. High homocysteine (tHcy) is also associated with a faster rate of brain atrophy. The VITACOG trial tested whether high-doses of B vitamins (folic acid, vitamins B6 and B12) could slow brain atrophy in people with MCI.

 Read more:



Updated:  23 October 2017/Responsible Officer:  Director/Page Contact:  Business Manager